Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICON-1 in Uveal Melanoma
NCT02771340Phase 1Completed
- Sponsor
- Iconic Therapeutics, Inc.
- Start
- May 2016
- Primary completion
- Sep 2017
- Modality
- Inhalation Devices, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of ICON-1 in Uveal melanoma (UM) (3 arms), sponsored by Iconic Therapeutics, Inc. Primary endpoint: Occurrence of Adverse Events. Started May 2016; status: completed.
02
Drugs
ICON-1
03
Conditions
Uveal melanoma (UM)
Beyond the preview
Go deeper on NCT02771340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02771340.